Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast CancersRayan Dakroub(Lebanese University), Thierry Dubois(Translational Research Institute)Breast Cancer Targets and TherapyNovember 1, 202310.2147/bctt.s430513Cited by 8SaveCiteExport RISWatch citationsRelated PapersFrequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells|Breast Cancer Research|2008|211TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer|PLoS ONE|2013|168Transcriptome Analysis of Wnt3a-Treated Triple-Negative Breast Cancer Cells|PLoS ONE|2015|89PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer|Cancers|2022|35LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers|Oncotarget|2018|33